Improving the discovery of antibody treatments using machine learning
REPTOR: accelerating antibody discovery and improving hits with machine learning
This study is working on a new way to find better antibody treatments for diseases like autoimmune conditions and COVID-19, using smart software to speed up the process, so patients can get effective treatments more quickly.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abterra Biosciences, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-10822485 on NIH RePORTER |
What this research studies
This research focuses on enhancing the process of discovering antibody therapeutics, which are crucial for treating various diseases, including autoimmune conditions and COVID-19. By developing advanced software that integrates high-throughput sequencing with existing antibody discovery methods, the project aims to streamline and improve the success rate of identifying effective antibodies. The approach leverages the natural immune responses of individuals to better inform the selection of therapeutic candidates. Patients may benefit from faster and more effective antibody treatments as a result of this innovative methodology.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with autoimmune diseases or those affected by COVID-19 who may benefit from new antibody treatments.
Not a fit: Patients who do not have autoimmune diseases or COVID-19 may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to quicker and more effective antibody therapies for patients with various diseases.
How similar studies have performed: Other research has shown promise in using high-throughput sequencing for antibody discovery, indicating that this approach could be a significant advancement in the field.
Where this research is happening
San Diego, United States
- Abterra Biosciences, INC. — San Diego, United States (Active)
Researchers
- Principal investigator: Castellana, Natalie — Abterra Biosciences, INC.
- Study coordinator: Castellana, Natalie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.